Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study
TipRanks (Mon, 22-Dec 11:30 AM ET)
Edwards Lifesciences upgraded at JP Morgan on TAVR, TMTT strength
Seeking Alpha News (Thu, 18-Dec 2:03 PM ET)
Edwards Lifesciences Sets Stage for Key Insights at J.P. Morgan Healthcare Conference
Market Chameleon (Thu, 18-Dec 3:23 AM ET)
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Thu, 18-Dec 7:05 AM ET)
TipRanks (Thu, 18-Dec 5:05 AM ET)
RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
TipRanks (Wed, 17-Dec 8:47 PM ET)
Business Wire (Thu, 4-Dec 9:00 AM ET)
PRNewswire (Sun, 30-Nov 3:29 PM ET)
Business Wire (Sun, 9-Nov 4:00 PM ET)
Edwards Lifesciences Announces CFO Transition Plan
Business Wire (Thu, 30-Oct 4:15 PM ET)
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Edwards Lifesciences trades on the NYSE stock market under the symbol EW.
As of December 22, 2025, EW stock price climbed to $86.53 with 2,225,575 million shares trading.
EW has a beta of 0.45, meaning it tends to be less sensitive to market movements. EW has a correlation of 0.11 to the broad based SPY ETF.
EW has a market cap of $50.21 billion. This is considered a Large Cap stock.
Last quarter Edwards Lifesciences reported $2 billion in Revenue and $.67 earnings per share. This beat revenue expectation by $55 million and exceeded earnings estimates by $.08.
In the last 3 years, EW traded as high as $96.12 and as low as $58.93.
The top ETF exchange traded funds that EW belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
EW has underperformed the market in the last year with a return of +17.0%, while SPY returned +18.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EW shares. However, EW has outperformed the market in the last 3 month and 2 week periods, returning +16.3% and +0.4%, while SPY returned +3.5% and +0.2%, respectively. This indicates EW has been having a stronger performance recently.
EW support price is $84.43 and resistance is $86.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EW shares will trade within this expected range on the day.